MRC1 and colorectal carcinoma: As mentioned above, for MMR deficient CRC patients, a phase I/II clinical trial with a peptide vaccine directed against AIM2, HT001 and TAF1B neoantigens employing the adjuvant Montanide ISA-51VG showed no severe toxicity in any of the patients while cellular and humoral immunogenic responses were seen in all 16 patients included in the study [57].